Nordea Investment Management
ALXN

Nordea Investment Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Nordea Investment Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-66,189
Closed -$12.2M – 1008
2021
Q2 		$12.2M Sell
66,189
-11,739
-15% -$2.02M 0.02% 364
2021
Q1 		$12M Buy
77,928
+2,142
+3% +$331K 0.02% 353
2020
Q4 		$11.8M Buy
75,786
+5,763
+8% +$741K 0.02% 345
2020
Q3 		$7.97M Sell
70,023
-41,685
-37% -$4.5M 0.01% 360
2020
Q2 		$12.5M Buy
111,708
+56,372
+102% +$5.98M 0.01% 384
2020
Q1 		$4.81M Sell
55,336
-619
-1% -$60.8K 0.01% 428
2019
Q4 		$6.01M Buy
55,955
+13,798
+33% +$1.48M 0.01% 417
2019
Q3 		$4.12M Buy
42,157
+171
+0.4% +$19.3K 0.01% 589
2019
Q2 		$5.5M Buy
41,986
+5,884
+16% +$758K 0.01% 433
2019
Q1 		$4.88M Buy
36,102
+24,041
+199% +$2.99M 0.01% 584
2018
Q4 		$1.17M Buy
12,061
+4
+0% +$473 ﹤0.01% 937
2018
Q3 		$1.68M Sell
12,057
-93,843
-89% -$11.8M ﹤0.01% 917
2018
Q2 		$13.1M Buy
105,900
+3,280
+3% +$383K 0.03% 288
2018
Q1 		$11.4M Sell
102,620
-2,327
-2% -$278K 0.03% 288
2017
Q4 		$12.6M Buy
104,947
+497
+0.5% +$60.5K 0.03% 276
2017
Q3 		$14.7M Buy
104,450
+5,572
+6% +$757K 0.04% 244
2017
Q2 		$12M Buy
98,878
+87,430
+764% +$10.2M 0.03% 259
2017
Q1 		$1.39M Buy
11,448
+1,598
+16% +$206K ﹤0.01% 728
2016
Q4 		$1.21M Buy
9,850
+653
+7% +$79.9K ﹤0.01% 683
2016
Q3 		$1.13M Buy
9,197
+239
+3% +$30.8K ﹤0.01% 665
2016
Q2 		$1.05M Sell
8,958
-87,579
-91% -$12.4M ﹤0.01% 532
2016
Q1 		$13.4M Buy
96,537
+26,568
+38% +$3.9M 0.04% 214
2015
Q4 		$13.3M Buy
69,969
+26,731
+62% +$4.67M 0.05% 211
2015
Q3 		$6.76M Buy
43,238
+8,247
+24% +$1.5M 0.02% 233
2015
Q2 		$6.33M Buy
34,991
+6,213
+22% +$1.07M 0.02% 249
2015
Q1 		$4.99M Buy
28,778
+12,221
+74% +$2.21M 0.02% 259
2014
Q4 		$3.06M Sell
16,557
-681
-4% -$126K 0.01% 298
2014
Q3 		$2.86M Sell
17,238
-3,258
-16% -$535K 0.01% 311
2014
Q2 		$3.2M Sell
20,496
-12,000
-37% -$1.89M 0.01% 346
2014
Q1 		$4.94M Sell
32,496
-1,287
-4% -$205K 0.02% 286
2013
Q4 		$4.49M Buy
33,783
+922
+3% +$111K 0.02% 302
2013
Q3 		$3.82M Sell
32,861
-83,133
-72% -$9.12M 0.02% 319
2013
Q2 		$10.7M Buy
+115,994
New +$11.2M 0.07% 192

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Nordea Investment Management's ALXN Position: Q3 2021 in Review

Nordea Investment Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 66,189 shares — an estimated $12.2M sold.

Nordea Investment Management first reported a position in ALXN in Q2 2013 and held it in 33 quarters. The position peaked at $14.7M in Q3 2017. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Nordea Investment Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Nordea Investment Management sold 66,189 Alexion Pharmaceuticals shares in Q3 2021, an estimated $12.2M.
  • Nordea Investment Management first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 33 quarters.
  • Nordea Investment Management's Alexion Pharmaceuticals position peaked at $14.7M in Q3 2017.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Nordea Investment Management's 13F filing for Q3 2021, filed 1 Nov 2021.